BioLife Solutions Reports Second Quarter 2025 Financial Results
Cell Processing revenue of $23.0 million, up 28% over Q2 2024 GAAP gross margin of 62%and non-GAAP adjusted gross margin of 65% GAAP net loss of $15.8 million, inclusive of a non-cash $15.5 million IPR&D expense, and non-GAAP adjusted EBITDA of $6.1 million or 24% of revenue Raises full-year 2025 revenue guidance to $100.0 million […]